|
1
|
Anninga JK, Gelderblom H, Fiocco M, Kroep
JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic
adjuvant treatment for osteosarcoma: Where do we stand? Eur J
Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kansara M, Teng MW, Smyth MJ and Thomas
DM: Translational biology of osteosarcoma. Nat Rev Cancer.
14:722–735. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ritter J and Bielack SS: Osteosarcoma. Ann
Oncol. 21 (Suppl 7):vii320–325. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferrari S and Serra M: An update on
chemotherapy for osteosarcoma. Expert Opin Pharmacother.
16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moriarity BS, Otto GM, Rahrmann EP, Rathe
SK, Wolf NK, Weg MT, Manlove LA, LaRue RS, Temiz NA, Molyneux SD,
et al: A Sleeping Beauty forward genetic screen identifies new
genes and pathways driving osteosarcoma development and metastasis.
Na Genet. 47:615–624. 2015. View
Article : Google Scholar
|
|
6
|
Baranski Z, Booij TH, Cleton-Jansen AM,
Price LS, van de Water B, Bovée JV, Hogendoorn PC and Danen EH:
Aven-mediated checkpoint kinase control regulates proliferation and
resistance to chemotherapy in conventional osteosarcoma. J Pathol.
236:348–359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holmboe L, Andersen AM, Mørkrid L, Slørdal
L and Hall KS: High dose methotrexate chemotherapy:
Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br
J Clin Pharmacol. 73:106–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wallin M, Barregard L, Sallsten G, Lundh
T, Karlsson MK, Lorentzon M, Ohlsson C and Mellström D: Low-level
cadmium exposure is associated with decreased bone mineral density
and increased risk of incident fractures in elderly men: The MrOS
Sweden Study. J Bone Miner Res. 31:732–741. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akesson A, Bjellerup P, Lundh T, Lidfeldt
J, Nerbrand C, Samsioe G, Skerfving S and Vahter M: Cadmium-induced
effects on bone in a population-based study of women. Environ
Health Perspect. 114:830–834. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Coogan TP, Achanzar WE and Waalkes MP:
Spontaneous transformation of cultured rat liver (TRL 1215) cells
is associated with down-regulation of metallothionein: Implications
for sensitivity to cadmium cytotoxicity and genotoxicity. J Environ
Pathol Toxicol Oncol. 19:261–273. 2000.PubMed/NCBI
|
|
11
|
Benbrahim-Tallaa L, Waterland RA, Dill AL,
Webber MM and Waalkes MP: Tumor suppressor gene inactivation during
cadmium-induced malignant transformation of human prostate cells
correlates with overexpression of de novo DNA methyltransferase.
Environ Health Perspect. 115:1454–1459. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie D and Sheng Z: Low-level cadmium
exposure and bone health. J Bone Miner Res. 32:4192017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kahler SC: Integrating cultural
competence: Animal health, food safety ultimately benefit as AVMA
incorporates cultural competence in CE. J Am Vet Med Assoc.
242:1186–1187. 2013.PubMed/NCBI
|
|
15
|
Rice ASC, Morland R, Huang W, Currie GL,
Sena ES and Macleod MR: Transparency in the reporting of in vivo
pre-clinical pain research: The relevance and implications of the
ARRIVE (Animal research: Reporting in vivo experiments) guidelines.
Scand J Pain. 4:58–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jaffe N: Osteosarcoma: Review of the past,
impact on the future. The American experience. Cancer Treat Res.
152:239–262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Do SI, Jung WW, Kim HS and Park YK: The
expression of epidermal growth factor receptor and its downstream
signaling molecules in osteosarcoma. Int J Oncol. 34:797–803.
2009.PubMed/NCBI
|
|
19
|
Man TK, Lu XY, Jaeweon K, Perlaky L,
Harris CP, Shah S, Ladanyi M, Gorlick R, Lau CC and Rao PH:
Genome-wide array comparative genomic hybridization analysis
reveals distinct amplifications in osteosarcoma. BMC Cancer.
4:452004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lau CC, Harris CP, Lu XY, Perlaky L,
Gogineni S, Chintagumpala M, Hicks J, Johnson ME, Davino NA, Huvos
AG, et al: Frequent amplification and rearrangement of chromosomal
bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes, Chromos Cancer.
39:11–21. 2004. View Article : Google Scholar
|
|
21
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-Where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Martelli L, Di Mario F, Botti P, Ragazzi
E, Martelli M and Kelland L: Accumulation, platinum-DNA adduct
formation and cytotoxicity of cisplatin, oxaliplatin and
satraplatin in sensitive and resistant human osteosarcoma cell
lines, characterized by p53 wild-type status. Biochem Pharmacol.
74:20–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang Q, Dexheimer TS, Zhang P, Rosenthal
AS, Villamil MA, You C, Zhang Q, Chen J, Ott CA, Sun H, et al: A
selective USP1-UAF1 inhibitor links deubiquitination to DNA damage
responses. Nat Chem Biol. 10:298–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levy JM, Towers CG and Thorburn A:
Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shibata A, Moiani D, Arvai AS, Perry J,
Harding SM, Genois MM, Maity R, van Rossum-Fikkert S, Kertokalio A,
Romoli F, et al: DNA double-strand break repair pathway choice is
directed by distinct MRE11 nuclease activities. Mol Cell. 53:7–18.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koo CY, Muir KW and Lam EW: FOXM1: From
cancer initiation to progression and treatment. Biochim Biophys
Acta. 1819:28–37. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Uddin S, Hussain AR, Ahmed M, Siddiqui K,
Al-Dayel F, Bavi P and Al-Kuraya KS: Overexpression of FoxM1 offers
a promising therapeutic target in diffuse large B-cell lymphoma.
Haematologica. 97:1092–1100. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang M and Gartel AL: The suppression of
FOXM1 and its targets in breast cancer xenograft tumors by siRNA.
Oncotarget. 2:1218–1226. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pandit B and Gartel AL: FoxM1 knockdown
sensitizes human cancer cells to proteasome inhibitor-induced
apoptosis but not to autophagy. Cell Cycle. 10:3269–3273. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nestal de Moraes G, Bella L, Zona S,
Burton MJ and Lam EW: Insights into a critical role of the
FOXO3a-FOXM1 axis in DNA damage response and genotoxic drug
resistance. Curr Drug Targets. 17:164–177. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Peake BF, Eze SM, Yang L, Castellino RC
and Nahta R: Growth differentiation factor 15 mediates epithelial
mesenchymal transition and invasion of breast cancers through
IGF-1R-FoxM1 signaling. Oncotarget. 8:94393–94406. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Khongkow P, Karunarathna U, Khongkow M,
Gong C, Gomes AR, Yagüe E, Monteiro LJ, Kongsema M, Zona S, Man EP,
et al: FOXM1 targets NBS1 to regulate DNA damage-induced senescence
and epirubicin resistance. Oncogene. 33:4144–4155. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zerlin M, Julius MA and Kitajewski J:
Wnt/Frizzled signaling in angiogenesis. Angiogenesis. 11:63–69.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Oltvai ZN, Milliman CL and Korsmeyer SJ:
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that
accelerates programmed cell death. Cell. 74:609–619. 1993.
View Article : Google Scholar : PubMed/NCBI
|
